Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Genitourinary 1Gastrointestinal 1

Conditions

Multiple Myeloma 1112Recurrence 195Neoplasms 89Lymphoma 89Neoplasms, Plasma Cell 88Lymphoma, Non-Hodgkin 86Leukemia, Myeloid, Acute 53Hematologic Neoplasms 51Leukemia, Lymphocytic, Chronic, B-Cell 44Leukemia 37Myelodysplastic Syndromes 33Lymphoma, Large B-Cell, Diffuse 31Hodgkin Disease 31Immunoglobulin Light-chain Amyloidosis 30Breast Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Hematologic Diseases 25Prostatic Neoplasms 19Paraproteinemias 19Lymphoma, B-Cell 19Amyloidosis 19Lymphoma, Mantle-Cell 18Ovarian Neoplasms 17Carcinoma, Non-Small-Cell Lung 17Waldenstrom Macroglobulinemia 16Lung Neoplasms 16Lymphoma, Follicular 15Lymphoproliferative Disorders 14Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14Blood Protein Disorders 14

Interventions

Pharmaceutical Preparations 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Nephrotic Syndrome × Plasma cell × Clear all
NCT00035334 2006-02-14

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Bellus Health Inc. - a GSK company

Phase 2/3 Completed
150 enrolled
GastrointestinalGenitourinaryPlasma cell

Amyloidosis, Arthritis, Rheumatoid, Gastrointestinal Diseases, Kidney Diseases, Neoplasm Metastasis, Nephrotic Syndrome, Familial Mediterranean Fever

Data powered by HemOnc (CC BY 4.0) Colophon âš¡